© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Paul Cottu, MD, MSc, medical oncologist, Institut Curie, Paris, discusses safety and pharmacokinetic (PK) results from phase I of an ongoing phase I-II study of onapristone (ONA) in patients with progesterone receptor (PR)-expressing cancers.